Filtered By:
Infectious Disease: Influenza
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 693 results found since Jan 2013.
COVID-19 Pandemic and Influenza Season in Hospitalized Patients: Concerns and Suggestions
Iran J Allergy Asthma Immunol. 2021 Jun 6;20(3):382-383. doi: 10.18502/ijaai.v20i3.6340.ABSTRACTThis is a letter to the editor.PMID:34134459 | DOI:10.18502/ijaai.v20i3.6340
Source: Iranian Journal of Allergy, Asthma and Immunology - June 17, 2021 Category: Allergy & Immunology Authors: Amir Hossein Norooznezhad Source Type: research
What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
NIH launches clinical trial of universal influenza vaccine candidate
(NIH/National Institute of Allergy and Infectious Diseases) A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIAID developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds.
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2021 Category: Infectious Diseases Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Will You Need a Booster Shot of the COVID-19 Vaccine?
When the first COVID-19 vaccines from Pfizer-BioNTech and Moderna were authorized by the U.S. Food and Drug Administration in December 2020, most people breathed a sigh of relief since both shots were shown to be between 94% and 95% effective in protecting from COVID-19 symptoms. But public health experts warned that nobody really knew how long the protection would last, since the longest clinical trials in people only went to a few months. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and the chief medical advisor to President Joe Biden, suggested that additional booster ...
Source: TIME: Health - April 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
UGA to establish national NIH-funded center to fight flu
(University of Georgia) The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.
Source: EurekAlert! - Biology - April 15, 2021 Category: Biology Source Type: news
NIAID funds new influenza research network
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks. The program, called the Centers of Excellence for Influenza Research and Response (CEIRR), is expected to be supported for seven years by NIAID contracts to five institutions. Funding for the first year of the contracts will total approximately $24 million.
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2021 Category: Infectious Diseases Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Evaluating the impact of COVID-19 on asthma morbidity: a comprehensive analysis of potential influencing factors
CONCLUSION: Our data confirm reduced healthcare utilization and suggest better asthma control during COVID-19, except for African Americans. This was associated with a significant increase in telehealth visits and reductions in PM2.5 and influenza infections, but not better asthma controller adherence.PMID:33775900 | DOI:10.1016/j.anai.2021.03.018
Source: Annals of Allergy, Asthma and Immunology - March 29, 2021 Category: Allergy & Immunology Authors: Olga L Guijon Tricia Morphew Morphew Consulting Louis Ehwerhemuepha Stanley P Galant Source Type: research
